The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study).
Hizal M, Bilgin B, Paksoy N, Atcı MM, Kahraman S, Kılıçkap S, Güven DC, Keskinkılıç M, Ayhan M, Eren Ö, Mustafayev FNA, Yaman Ş, Bayram E, Ertürk İ, Özcan E, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, Baytemür NK, Gülmez A, Aydın D, Şakalar T, Arak H, Tatlı AM, Ergün Y, Ak N, Ünal Ç, Özgün MA, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Şendur MAN.J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2. Online ahead of print.
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.
Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310. Epub 2022 Jun 20.PMID: 35703239
Özdemir Ö, Zengel B, Yildiz Y, Uluç BO, Cabuk D, Ozden E, Salim DK, Paydas S, Demir A, Diker O, Pilanci KN, Sönmez ÖU, Vatansever S, Dogan I, Gulmez A, Cakar B, Gursoy P, Yildirim ME, Ayhan M, Karadurmus N, Aykan MB, Cevik GT, Sakalar T, Hacibekiroglu I, Gülbagci BB, Dincer M, Garbioglu DB, Kemal Y, Nayir E, Taskaynatan H, Yilmaz M, Avci O, Sari M, Coban E, Atci MM, Esen SA, Telli TA, Karatas F, Inal A, Demir H, Kalkan NO, Yilmaz C, Tasli F, Alacacioglu A.
External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.
Genitourin Cancer. 2022 Jul 16:S1558-7673(22)00158-6. doi: 10.1016/j.clgc.2022.07.006. Online ahead of print.PMID: 35970759
Yekedüz E, Karakaya S, Ertürk İ, Tural D, Uçar G, Şentürk Öztaş N, Arıkan R, Hızal M, Küçükarda A, Sever ÖN, Arslan Ç, Can O, Kılıçkap S, Yazgan C, Karadurmuş N, Şendur MA, Çiçin İ, Demirci U, Özgüroğlu M, Öksüzoğlu B, Ürün Y.Clin
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.
Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083. Epub 2022 Jun 23.PMID: 35734870
Hizal M, Bilgin B, Paksoy N, Kılıçkap S, Atcı MM, Kahraman S, Keskinkılıç M, Bilgetekin İ, Ayhan M, Tural D, Eren Ö, Akkoç Mustafayev FN, Yaman Ş, Tatlı AM, Bayram E, Kutlu Y, Ertürk İ, Özcan E, Gülmez A, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, İriağaç Y, Baytemür NK, Aydın D, Şakalar T, Arak H, Selçukbiricik F, Ergün Y, Korkmaz T,Ak N, Ünal Ç, Akdeniz N, Özgün MA, Öksüzoğlu B, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Şendur MAN.
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group.
J Cancer Res Clin Oncol. 2022 Jun 11. doi: 10.1007/s00432-022-04087-x. Online ahead of print.PMID: 35689097
Gürbüz M, Kutlu Y, Akkuş E, Köksoy EB, Köse N, Öven BB, Uluç BO, Demiray AG, Erdem D, Demir B, Turhal NS, Üskent N, Akbaş S, Selçukbiricik F, İnal A, Bilici A, Ölmez ÖF, Çabuk D, Ünal Ç, Hızal M, Şendur MAN, Korkmaz M, Karadurmuş N, Ertürk İ, Göksu SS, Tatlı AM, Güven DC, Kılıçkap S, Paksoy N, Aydıner A, Çınkır HY, Özkul Ö, Öztürk A, Ballı S, Kemal Y, Erdoğan AP, Er Ö, Yumuk PF, Demirkazık A.
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.
J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7. Epub 2021 Jul 31.PMID: 34331582
Hizal M, Bilgin B, Paksoy N, Açıkgöz Ö, Sezer A, Gürbüz M, Ak N, Yücel Ş, Ayhan M, Erol C, Demirkıran A, Mandel NM, Shbair A, Gökmen İ, Başoğlu T, Paydaş S, Demiray AG, İriağaç Y, Şakalar T, Zeynelgil E, Tatlı AM, Bahçeci A, Güven DC, Caner B, Can A, Gülmez A, Karakaş Y, Yalçın B, Demirkazık A, Bilici A, Aydıner A, Yumuk PF, Şendur MAN.
The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: a Turkish Oncology Group (TOG) Study.
J Gastrointest Cancer. 2022 Jun;53(2):356-362. doi: 10.1007/s12029-021-00602-4. Epub 2021 Mar 3.PMID: 33656690
NazimTurhal S, Dogan M, Esendagli G, Artac M, Korkmaz L, Coskun HS, Goker E, PerranYumuk F, Bilgetekin I, Kose F, Uncu D, Kavgaci H, Akyol G, Ozet A, Yagci T.
Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group.
J Gastrointest Cancer. 2022 Jun;53(2):282-288. doi: 10.1007/s12029-021-00594-1. Epub 2021 Feb 4.PMID: 33538958
Gürbüz M, Akkuş E, Sakin A, Urvay S, Demiray AG, Şahin S, Şakalar T, Erol C, Şendur MAN, Şahin AB, Çubukçu E, Güven DC, Kılıçkap S, Ergün Y, Uncu D, Turhal NS, Üskent N, Çınkır HY, Demir A, Acar R, Karadurmuş N, Türker S, Altınbaş M, Karaoğlan M, Şenler FÇ.
The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study.
J Cancer Res Clin Oncol. 2022 May 26. doi: 10.1007/s00432-022-04055-5. Online ahead of print.PMID: 35616728
Yekedüz E, Tural D, Ertürk İ, Karakaya S, Erol C, Ercelep Ö, Arslan Ç, Sever ÖN, Kılıçkap S, Şentürk Öztaş N, Küçükarda A, Can O, Öksüzoğlu B, Şendur MA, Karadurmuş N, Ürün Y.
Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study.
J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159. Online ahead of print.PMID: 35579894
Başoğlu T, Sakin A, Erol C, Özden E, Çabuk D, Çılbır E, Tataroğlu Özyükseler D, Ayhan M, Şendur MA, Dogan M, Öksüzoğlu B, Eryılmaz MK, Er Ö, Taşçı EŞ, Özyurt N, Dülgar Ö, Özen M, Hacıbekiroğlu İ, Öner İ, Bekmez ET, Çağrı Yıldırım H, Yalçın Ş, Paydaş S, Yekedüz E, Aksoy A, Özçelik M, Oyman A, Almuradova E, Karabulut B, Demir N, Dinçer M, Özdemir N, Erdem D, Ak N, İnal A, Salim DK, Deniz Gİ, Şakalar T, Gülmez A, Kaçan T, Özdemir Ö, Alan Ö, Ünal Ç, Karakaş Y, Turhal S, Yumuk PF.
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
J Cancer Res Clin Oncol. 2022 Apr 5. doi: 10.1007/s00432-022-03984-5. Online ahead of print.PMID: 35381885
Gursoy P, Tatli AM, Erdem D, Goker E, Celik E, Demirci NS, Sakin A, Atci MM, Bayram E, Telli TA, Bilgin B, Bilici A, Akangunduz B, Balli S, Demirkazik A, Selçukbiricik F, Menekse S, Cavdar E, Ozturk A, Bekmez ET, Turhal S, Kilickap S, Yildirim HÇ, Oyan B, Aksoy A, Turkoz FP, Kut E, Katgi N, Sakalar T, Akyol M, Ellez Hİ, Topcu A, Erdoğan AP, Pilanci KN, Hedem E, Arak H, Akdeniz N, Alan Ö, Yapar B, Nart D, Yumuk PF.
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study.
Cancer Invest. 2022 Feb;40(2):199-209. doi: 10.1080/07357907.2021.2017952. Epub 2021 Dec 22.PMID: 34894960
Bilici A, Uysal M, Menekse S, Akin S, Yildiz F, Turan M, Sezgin Goksu S, Beypinar I, Sakalar T, Değirmenci M, Erdem D, Basaran G, Olmez OF, Avci N, Tural D, Sakin A, Turker S, Demir A, Temiz S, Kaplan MA, Dogan M, Tanriverdi O, Bilgetekin I, Cinkir HY, Acikgoz O, Paydas S, Uslu R, Turhal S.
The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: a Turkish Oncology Group (TOG) Study. J Gastrointest Cancer. 2021 Mar 3. doi: 10.1007/s12029-021-00602-4. Epub ahead of print. PMID: 33656690.
NazimTurhal S, Dogan M, Esendagli G, Artac M, Korkmaz L, Coskun HS, Goker E, PerranYumuk F, Bilgetekin I, Kose F, Uncu D, Kavgaci H, Akyol G, Ozet A, Yagci
Trastuzumab ± Capecitabine Maintenance After the First- Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group. J Gastrointest Cancer.
2021 Feb 4. doi: 10.1007/s12029-021-00594-1. Epub ahead of print. PMID: 33538958.
Gürbüz M, Akkuş E, Sakin A, Urvay S, Demiray AG, Şahin S, Şakalar T, Erol C,Şendur MAN, Şahin AB, Çubukçu E, Güven DC, Kılıçkap S, Ergün Y, Uncu D, Turhal NS, Üskent N, Çınkır HY, Demir A, Acar R, Karadurmuş N, Türker S, Altınbaş M, Karaoğlan M, Şenler FÇ.
Factors Affecting Survival in Retroperitoneal Sarcomas Treated with Upfront Surgery: A Real-World Study by Turkish Oncology Group’. Int J Hemat Oncol (UHOD), 31(1), (2021). doi: 10.4999/uhod.
Akagunduz B, Akin Telli T, Yıldırım HC, Sezgin Goksu S, Demir N, Hafızoglu E, Ozer M, Cevik GT, Sakin A, Aydın SG, Samancı NS, Ozyurt N, Atcı MM, Ayhan M, Turan M, Sarıyar N, Karacin C, Kılıckap S, Paydas S, Dogan M.
Assessment of Prognostic Factors and Adjuvant Treatment Modalities in Adult Head and Neck Soft Tissue Sarcoma Patients Treated With Upfront Surgery.
Akagündüz B, Akin Telli T, Sezgin Goksu S, Yildirim HC, Ozer M, Göktaş Aydin S, Ozyurt N, Karacin C, Paydas S, Dogan M. Cureus. 2021 Feb 13;13(2):e13324. doi: 10.7759/cureus.13324.
F. Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer. Tumori. 2020 Nov 9:300891620969823. doi: 10.1177/0300891620969823. Epub ahead of print. PMID: 33167790.
Gürbüz M, Akkuş E, Sakin A, Urvay S, Demiray AG, Şahin S, Şakalar T, Erol C, Şendur MAN, Şahin AB, Çubukçu E, Güven DC, Kılıçkap S, Ergün Y, Uncu D, Turhal NS, Üskent N, Yeşil Çınkır H, Demir A, Acar R, Karadurmuş N, ürker S, Altınbaş M, Karaoğlan M, Çay Şenler
Demographical and Clinical Features of Marginal Zone Lymphomas: A Retrospective Study of Turkish Oncology Group (TOG). Indian J Hematol Blood Transfus. 2020 Oct;36(4):640-645. doi: 10.1007/s12288-020-01257-0. Epub 2020 Feb 22. PMID: 33100705; PMCID: PMC7573056.
Türkkan G, Alkan A, Paydaş S, Tanrıverdi Ö, Karakaş Y, Karadurmuş N, Sakin A, Temiz S, Arpacı E, Akın M, Menekşe S, Şen CA, Barışta İ.
The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study. J Gastrointest Cancer. 2020 Sep 11. doi: 10.1007/s12029-020-00514-9. Epub ahead of print. PMID: 32914373.
Beypinar I, Demir H, Sakin A, Taskoylu BY, Sakalar T, Ergun Y, Korkmaz M, Ates O, Eren T, Turhal S, Artac M. The
Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). Eur J Cancer Care (Engl). 2020
Nov;29(6):e13296. doi: 10.1111/ecc.13296. Epub 2020 Aug 30. PMID: 32864838.
Alkan A, Yaşar A, Güç ZG, Gürbüz M, Başoğlu T, Sezgin Göksu S, Buğdaycı Başal F, Türk HM, Özdemir Ö, Yeşil Çınkır H, Güven DC, Kuş T, Türker S, Koral L, Karakaş Y, Ak N, Paydaş S, Karcı E, Demiray AG, Demir A, Alan Ö, Keskin Ö, Nayır E, Tanrıverdi Ö, Yavuzşen T, Yumuk PF, Ateş Ö, Coşkun HŞ, Turhal S, Çay Şenler
Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study. J BUON. 2020 Mar-Apr;25(2):1130-1135. PMID: 32521916.
Yildiz B, Kucukarda A, Gokyer A, Gokcen Demiray A, Paydas S, Pinar Aral I, Gumusay O, Bilici A, Akdeniz N, Bahceci A, Demir H, Esin E, Üyeturk U, Nihat Okten I, Erturk I, Turk HM, Topaloglu US, Basoglu T, Serdar Turhal N, Yesil Cinkir H, Menekse S, Cakmak Y, Urun Y, Acar R, Kut E, Dal P, Sakalar T, Halit Aktepe O, Karadurmus N, Bilici A.
Risk factors of radiation pneumonitis in patients with NSCLC treated with concomitant chemoradiotherapy–Are we underestimating diabetes?–Turkish oncology group (TOG)/Lung cancer study group. Clin Respir J. 2020 Sep;14(9):871-879. doi: 10.1111/crj.13220. Epub 2020 Jun 23. PMID: 32470205.
Ergen SA, Dincbas FO, Yücel B, Altınok P, Akyurek S, Korkmaz Kıraklı E, Ulger S, Etiz D, Yilmaz U, Kılıc D, Bozcuk H.
Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma
(Turkish Oncology Group Study). J Oncol Pharm Pract. 2020 Oct;26(7):1583-1589. doi: 10.1177/1078155219900908. Epub 2020 Feb 13. PMID: 32054412.
Hizal M, Sendur MA, Yasar HA, Bir Yucel K, Arslan C, Ucar G, Karakaya S, Taban H, Kucukarda A, Erturk I, Bilgin B, Yıldırım N, Demirci U, Kılıckap S, Cicin I, Karadurmus N, Yalcin B, Ürün Y.
Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study. J Oncol Pharm Pract. 2020 Mar;26(2):267-272. doi: 10.1177/1078155219840796. Epub 2019 Mar 29. PMID:
Arzu Yaşar H, Turna H, Esin E, Murat Sedef A, Alkan A, Oksuzoglu B, Ozdemir N, Sendur MN, Sezer A, Kılıckap S, Utkan G, Akbulut H, Celik I, Abalı H, Urun Y.
Comments on “Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study”. J Oncol Pharm Pract. 2019 Dec;25(8):2060-2062. doi: 10.1177/1078155219858177. Epub 2019 Jun 21. PMID: 31226918.<
Yilmaz MT, Elmali A, Yazici G.
Addition of taxanes to combination chemotherapy in distal intestinal gastric cancer is more beneficial than proximal ones: A multicenter retrospective study of Turkish Oncology Group. J BUON. 2019 Mar-Apr;24(2):650-655. PMID: 31128019.
Murat Sedef A, Taner Sumbul FKA, Ayberk Besen A, Hacioglu B, Gunaldi M, Nayir E, Tanriverdi O, Arpaci E, Abali H, Ozyilkan O.
A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG). J BUON. 2019 Jan-Feb;24(1):136-142. PMID: 30941962.
Degirmencioglu S, Tanriverdi O, Menekse S, Dogan M, Hacıoglu B, Oktay E, Erdem D, Arpaci E, Uluc BO, Turhal S, Yilmaz M, Pilanci KN, Sakin A, Araz M, Cokmert S, Ozdemir O, Sen E, Nayir E.
The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group. Curr Probl Cancer. 2019 Aug;43(4):344-353. doi: 10.1016/j.currproblcancer.2018.09.002. Epub 2018 Nov 22. PMID: 30497851.
Araz M, Karaagac M, Korkmaz L, Beypinar I, Uysal M.
Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study. J Oncol Pharm Pract. 2019 Oct;25(7):1658-1664. doi: 10.1177/1078155218805539. Epub 2018 Nov 6. PMID: 30400750.
Urun Y, Yasar HA, Turna H, Esin E, Sedef AM, Alkan A, Oksuzoglu B, Ozdemir N, Sendur MN, Sezer A, Kılıckap S, Utkan G, Akman T, Akbulut H, Celik I, Abalı H.
Turkish Oncology Group. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes. Cancer Chemother Pharmacol. 2019 Jan;83(1):131-143. doi: 10.1007/s00280-018-3712-7. Epub 2018 Oct 30. PMID: 30377778.
Esin E, Oksuzoglu B, Bilici A, Cicin I, Kostek O, Kaplan MA, Aksoy S, Aktas BY, Ozdemir O, Alacacioglu A, Cabuk D, Sumbul AT, Sakin A, Paydas S, Yetisir E, Er O, Korkmaz T, Yildirim N, Sakalar T, Demir H, Artac M, Karaagac M, Harputluoglu H, Bilen E, Erdur E, Degirmencioglu S, Aliyev A, Cil T, Olgun P, Basaran G, Gumusay O, Demir A, Tanrikulu E, Yumuk PF, Imamoglu I, Oyan B, Cetin B, Haksoyler V, Karadurmus N, Erturk I, Evrensel T, Yilmaz H, Beypinar I, Kocer M, Pilanci KN, Seker M, Urun Y, Yildirim N, Eren T, Demirci U;
The mean platelet volume may predict the development of isolated bone metastases in patients with breast cancer: a retrospective study of the Young Researchers Committee of the Turkish Oncology Group (TOG). J BUON. 2016 Jul-Aug;21(4):840-850.
Tanriverdi O, Menekse S, Teker F, Oktay E, Nur Pilanc K, Gunaldi M, Kocar M, Kacan T, Bahceci A, Avci N, Akman T, Cokmert S, Yesil-Cinkir H, Teoman Yanmaz M.
Risk Factors of Radiation Pneumonitis in the Patients With Non-Small Cell Lung Cancer Treated by Concomitant Chemoradiation Therapy: TOG/TROD Lung Cancer Study Group. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E476-E477.
Ergen SA, Dincbas FO, Yucel B, Akyurek S, Ulger S, Etiz D, Korkmaz E, Yilmaz U, Senocak MS, Bozcuk H, Kılıc D.
Tendency of cancer patients and their relatives to use internet for health-related searches: Turkish Oncology Group (TOG) Study. J BUON. 2016 May-Jun;21(3):714-9
Nayir E, Tanriverdi O, Karakas Y, Kilickap S, Serdar Turhal N, Avci N, Okutur K, Koca D, Erdem D, Abali H, Yamac D, Bilir C, Kacan T.
Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study. Clin Genitourin Cancer. 2016 Aug;14(4):e347-53.
Artaç M, Çoşkun HŞ, Korkmaz L, Koçer M, Turhal NS, Engin H, Dede İ, Paydaş S, Öksüzoğlu B, Bozcuk H, Demirkazık A.
Breast cancer survivors suffer from persistent postmastectomy pain syndrome and posttraumatic stress disorder (ORTHUS study): a study of the palliative care working committee of the Turkish Oncology Group (TOG). Support Care Cancer. 2016 Sep;24(9):3747-55
Alkan A, Guc ZG, Senler FC, Yavuzsen T, Onur H, Dogan M, Karci E, Yasar A, Koksoy EB, Tanriverdi O, Turhal S, Urun Y, Ozkan A, Mizrak D, Akbulut H.
Depression and socio-economical burden are more common in primary caregivers of patients who are not aware of their cancer: TURQUOISE Study by the Palliative Care Working Committee of the Turkish Oncology Group (TOG). Eur J Cancer Care (Engl). 2016 May;25(3):502-15.
Tanriverdi O, Yavuzsen T, Turhal S, Kilic D, Yalcin S, Ozkan A, Uzunoglu S, Uysal-Sonmez O, Akman T, Aktas B, Ulger S, Babacan T, Komurcu S, Yaren A, Cay-Senler F.
Cancer Epidemiology and Prevention Committee of Turkish Oncology Group. Changes in lifestyle upon diagnosis of cancer or other chronic illnesses: A Turkish Oncology Group study. J Health Psychol. 2016 Jul 22. pii: 1359105316658968. [Epub ahead of print] PubMed PMID: 27450678
Turhal NS, Akinci F, Haciabdullahoglu Y, Dolmaci M, Sari A, Gurhan N, Mutlu A, Ozdemir F, Artac M, Kilickap S
Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. J Gastrointest Cancer. 2016 Sep;47(3):264-72.
Artaç M, Coşkun HŞ, Dane F, Karabulut B, Korkmaz L, Karaağaç M, Çabuk D, Karabulut S, Faruk Aykan N, Doruk H, Avcı N, Turhal NS.
Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study. Mol Clin Oncol. 2015 Nov;3(6):1275-1279.
Turhal NS, Savaş B, Çoşkun Ö, Baş E, Karabulut B, Nart D, Korkmaz T, Yavuzer D, Demir G, Doğusoy G, Artaç M.
Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial). Turk J Gastroenterol. 2015 Mar;26(2):145-53.
Aykan NF, Yalçın S, Turhal NS, Özdoğan M, Demir G, Özkan M, Yaren A, Camcı C, Akbulut H, Artaç M, Meydan N, Uygun K, Işıkdoğan A, Ünsal D, Özyılkan Ö, Arıcan A, Seyrek E, Tekin SB, Manavoğlu O, Özet A, Elkıran T, Dişçi R.
Perspectives and practical applications of medical oncologists on defensive medicine (SYSIPHUS study): a study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). Med Oncol. 2015 Apr;32(4):106.
Tanriverdi O, Cay-Senler F, Yavuzsen T, Turhal S, Akman T, Komurcu S, Cehreli R, Ozyilkan O.
Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG). Breast Cancer. 2015 Sep;22(5):480-5.
İçli F, Altundağ K, Akbulut H, Paydaş S, Başaran G, Saip P, Doğu GG, Eralp Y, Uslu R, Sevinç A, Onur H, Mandel NM, Sezgin C, Altınbaş M, Güler N, Işıkdoğan A, Gökmen E, Uygun K, Üstüner Z, Yaren A, Demirkan B, Coşkun U, Ata A, Özkan M, Arican A.
The Perspective of Non-oncologist Physicians on Patients with Metastatic Cancer and Palliative Care (ALONE Study): A Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). J Cancer Educ. 2015 Jun;30(2):253-9.
Tanriverdi O, Yavuzsen T, Akman T, Senler FC, Taskoylu BY, Turhal S, Komurcu S, Cehreli R, Yaren A, Ozyilkan O.
Investigational tests and treatments performed in terminal stage cancer patients in two weeks before death: Turkish oncology group (TOG) study. Med Oncol. 2014 Dec;31(12):350.
Türker İ, Kömürcü Ş, Arıcan A, Doruk H, Özyılkan Ö, Coşkun HŞ, Colak D, Üçgül Çavuşoğlu E, Ata A, Sezer A, Yeşil Çınkır H, Şenler FC, Arpacı F.
The clinical and pathological features of 133 colorectal cancer patients with brain metastasis: a multicenter retrospective analysis of the Gastrointestinal Tumors Working Committee of the Turkish Oncology Group (TOG). Med Oncol. 2014 Sep;31(9):152.
Tanriverdi O, Kaytan-Saglam E, Ulger S, Bayoglu IV, Turker I, Ozturk-Topcu T, Cokmert S, Turhal S, Oktay E, Karabulut B, Kilic D, Kucukzeybek Y, Oksuzoglu B, Meydan N, Kaya V, Akman T, Ibis K, Saynak M, Sen CA, Uysal-Sonmez O, Pilancı KN, Demir G, Saglam S, Kocar M, Menekse S, Goksel G, Yapar-Taskoylu B, Yaren A, Uyeturk U, Avci N, Denizli B, Ilis-Temiz E.
Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial. Anticancer Res. 2014 Aug;34(8):4329-34.
Yildiz I, Ekenel M, Akman T, Kocar M, Uysal M, Kanitez M, Varol U, Bayoglu IV, Tural D, Kaplan MA, Avci N, Sürmeli Z, Dede İ, Ulaş A, Yazici O, Basaran M.
Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study. Tumori. 2014 Mar-Apr;100(2):143-8.
Artac M, Turhal NS, Kocer M, Karabulut B, Bozcuk H, Yalcin S, Karaagac M, Gündüz S, Isik N, Uygun K.
Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. Cancer Chemother Pharmacol. 2014 Dec;74(6):1139-47.
Ozdemir N, Abali H, Vural M, Yalcin S, Oksuzoglu B, Civelek B, Oguz D, Bostanci B, Yalcin B, Zengin N.